Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
UTHR's Cash to Debt is ranked higher than
94% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. UTHR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
UTHR' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 28.04 Max: 15951.56
Current: No Debt
0.69
15951.56
Equity to Asset 0.81
UTHR's Equity to Asset is ranked higher than
68% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. UTHR: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
UTHR' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.68 Max: 0.97
Current: 0.81
0.37
0.97
Interest Coverage 466.45
UTHR's Interest Coverage is ranked lower than
67% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 466.45 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.2 Max: 466.45
Current: 466.45
2.02
466.45
F-Score: 7
Z-Score: 12.89
M-Score: -1.71
WACC vs ROIC
12.62%
97.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 65.38
UTHR's Operating margin (%) is ranked higher than
98% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. UTHR: 65.38 )
Ranked among companies with meaningful Operating margin (%) only.
UTHR' s Operating margin (%) Range Over the Past 10 Years
Min: -29.15  Med: 27.54 Max: 65.38
Current: 65.38
-29.15
65.38
Net-margin (%) 44.40
UTHR's Net-margin (%) is ranked higher than
96% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. UTHR: 44.40 )
Ranked among companies with meaningful Net-margin (%) only.
UTHR' s Net-margin (%) Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 46.33
Current: 44.4
-17.52
46.33
ROE (%) 42.08
UTHR's ROE (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. UTHR: 42.08 )
Ranked among companies with meaningful ROE (%) only.
UTHR' s ROE (%) Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 46.04
Current: 42.08
-11.59
46.04
ROA (%) 32.16
UTHR's ROA (%) is ranked higher than
98% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. UTHR: 32.16 )
Ranked among companies with meaningful ROA (%) only.
UTHR' s ROA (%) Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 32.16
Current: 32.16
-6.75
32.16
ROC (Joel Greenblatt) (%) 204.27
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. UTHR: 204.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
UTHR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43.1  Med: 67.4 Max: 215.39
Current: 204.27
-43.1
215.39
Revenue Growth (3Y)(%) 18.50
UTHR's Revenue Growth (3Y)(%) is ranked higher than
71% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. UTHR: 18.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
UTHR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 18.5  Med: 37.9 Max: 260.9
Current: 18.5
18.5
260.9
EBITDA Growth (3Y)(%) 32.40
UTHR's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. UTHR: 32.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
UTHR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: 15.9 Max: 128
Current: 32.4
-56.2
128
EPS Growth (3Y)(%) 30.60
UTHR's EPS Growth (3Y)(%) is ranked higher than
83% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. UTHR: 30.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
UTHR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.7  Med: 14.9 Max: 153.6
Current: 30.6
-50.7
153.6
GuruFocus has detected 3 Warning Signs with United Therapeutics Corp $UTHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UTHR's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

UTHR Guru Trades in Q1 2016

David Dreman 125 sh (New)
Ray Dalio 85,833 sh (+204.79%)
Lee Ainslie 20,930 sh (+98.01%)
Paul Tudor Jones 4,600 sh (+58.62%)
Joel Greenblatt 362,565 sh (+10.43%)
George Soros Sold Out
Ken Fisher 3,092 sh (-1.43%)
Jim Simons 474,578 sh (-14.04%)
» More
Q2 2016

UTHR Guru Trades in Q2 2016

David Dreman 2,670 sh (+2036.00%)
Lee Ainslie 26,710 sh (+27.62%)
Joel Greenblatt 367,075 sh (+1.24%)
Ken Fisher 3,092 sh (unchged)
Jim Simons 404,300 sh (-14.81%)
Paul Tudor Jones 3,700 sh (-19.57%)
Ray Dalio 64,100 sh (-25.32%)
» More
Q3 2016

UTHR Guru Trades in Q3 2016

Paul Tudor Jones 10,104 sh (+173.08%)
Ray Dalio 113,805 sh (+77.54%)
Ken Fisher 3,124 sh (+1.03%)
David Dreman 2,670 sh (unchged)
Lee Ainslie 25,910 sh (-3.00%)
Jim Simons 390,100 sh (-3.51%)
Joel Greenblatt 317,358 sh (-13.54%)
» More
Q4 2016

UTHR Guru Trades in Q4 2016

Ken Fisher 3,124 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:JAZZ, NAS:IONS, NAS:EXEL, NAS:SGEN, NAS:ARIA, NAS:TSRO, NAS:ALKS, NAS:TECH, NAS:ALNY, NAS:ACAD, NAS:GLPG, NAS:RARE, NAS:CBPO, NYSE:XON, NAS:ICPT, OTCPK:BTGGF, NAS:BLUE, NAS:KITE, NAS:CLVS, NAS:LGND » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered under the skin or in the vein for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor act to inhibit the degradation of cyclic guanosine monophosphate n cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products which include: Flolan, Ventavis, Ilomedin, Tracleer, Revatio, Letairis, Veletri, Adempas, Opsumit, generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.

Top Ranked Articles about United Therapeutics Corp

Gurus Invest in Top Biotechnology Stocks Graham’s Lost Formula unearths biotech gem; many guru buys occur
Throughout the first quarter, many gurus have increased their positions in top-performing biotechnology stocks, suggesting that the biotechnology sector contains some hot opportunities to increase portfolio returns. One of the hottest biotech stocks, United Therapeutics Corp. (NASDAQ:UTHR), is currently owned by seven gurus. Additionally, four gurus increased their position in United Therapeutics, one of eight biotechnology stocks listed on the Ben Graham’s Lost Formula I Screener. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 10.10
UTHR's P/E(ttm) is ranked higher than
84% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. UTHR: 10.10 )
Ranked among companies with meaningful P/E(ttm) only.
UTHR' s P/E(ttm) Range Over the Past 10 Years
Min: 4.95  Med: 22.81 Max: 171.34
Current: 10.1
4.95
171.34
Forward P/E 9.32
UTHR's Forward P/E is ranked higher than
87% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 17.86 vs. UTHR: 9.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.10
UTHR's PE(NRI) is ranked higher than
85% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 28.58 vs. UTHR: 10.10 )
Ranked among companies with meaningful PE(NRI) only.
UTHR' s PE(NRI) Range Over the Past 10 Years
Min: 4.95  Med: 22.68 Max: 171.34
Current: 10.1
4.95
171.34
Price/Owner Earnings (ttm) 15.73
UTHR's Price/Owner Earnings (ttm) is ranked higher than
71% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.43 vs. UTHR: 15.73 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
UTHR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.08  Med: 35.24 Max: 570.89
Current: 15.73
5.08
570.89
P/B 3.49
UTHR's P/B is ranked higher than
52% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. UTHR: 3.49 )
Ranked among companies with meaningful P/B only.
UTHR' s P/B Range Over the Past 10 Years
Min: 2.01  Med: 3.93 Max: 10.39
Current: 3.49
2.01
10.39
P/S 4.54
UTHR's P/S is ranked higher than
72% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. UTHR: 4.54 )
Ranked among companies with meaningful P/S only.
UTHR' s P/S Range Over the Past 10 Years
Min: 2.88  Med: 5.71 Max: 13.37
Current: 4.54
2.88
13.37
PFCF 15.83
UTHR's PFCF is ranked higher than
68% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. UTHR: 15.83 )
Ranked among companies with meaningful PFCF only.
UTHR' s PFCF Range Over the Past 10 Years
Min: 9.78  Med: 20.02 Max: 618.25
Current: 15.83
9.78
618.25
POCF 14.03
UTHR's POCF is ranked higher than
66% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. UTHR: 14.03 )
Ranked among companies with meaningful POCF only.
UTHR' s POCF Range Over the Past 10 Years
Min: 8.33  Med: 17.59 Max: 46.12
Current: 14.03
8.33
46.12
EV-to-EBIT 4.95
UTHR's EV-to-EBIT is ranked higher than
80% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. UTHR: 4.95 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 13.3 Max: 120.9
Current: 4.95
-31.2
120.9
EV-to-EBITDA 4.80
UTHR's EV-to-EBITDA is ranked higher than
80% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. UTHR: 4.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 12.4 Max: 102.2
Current: 4.8
-33.7
102.2
PEG 0.28
UTHR's PEG is ranked higher than
92% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. UTHR: 0.28 )
Ranked among companies with meaningful PEG only.
UTHR' s PEG Range Over the Past 10 Years
Min: 0.15  Med: 0.42 Max: 2.43
Current: 0.28
0.15
2.43
Shiller P/E 31.08
UTHR's Shiller P/E is ranked higher than
71% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 46.84 vs. UTHR: 31.08 )
Ranked among companies with meaningful Shiller P/E only.
UTHR' s Shiller P/E Range Over the Past 10 Years
Min: 22.69  Med: 48.75 Max: 679.13
Current: 31.08
22.69
679.13
Current Ratio 4.41
UTHR's Current Ratio is ranked higher than
52% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. UTHR: 4.41 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.42 Max: 64.22
Current: 4.41
0.96
64.22
Quick Ratio 4.11
UTHR's Quick Ratio is ranked higher than
52% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. UTHR: 4.11 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 5.2 Max: 64.22
Current: 4.11
0.9
64.22
Days Inventory 452.11
UTHR's Days Inventory is ranked lower than
93% of the 437 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. UTHR: 452.11 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 452.11
Current: 452.11
118.32
452.11
Days Sales Outstanding 51.41
UTHR's Days Sales Outstanding is ranked higher than
59% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. UTHR: 51.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.68 Max: 51.41
Current: 51.41
36.71
51.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. UTHR: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -1.4 Max: 4.3
Current: 3
-9.9
4.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.65
UTHR's Price/Net Cash is ranked lower than
68% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. UTHR: 10.65 )
Ranked among companies with meaningful Price/Net Cash only.
UTHR' s Price/Net Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.1 Max: 160.03
Current: 10.65
1.51
160.03
Price/Net Current Asset Value 6.71
UTHR's Price/Net Current Asset Value is ranked lower than
57% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. UTHR: 6.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
UTHR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.46  Med: 10.55 Max: 5533
Current: 6.71
1.46
5533
Price/Tangible Book 3.55
UTHR's Price/Tangible Book is ranked higher than
59% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. UTHR: 3.55 )
Ranked among companies with meaningful Price/Tangible Book only.
UTHR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 3.79 Max: 18.16
Current: 3.55
1.16
18.16
Price/Projected FCF 1.10
UTHR's Price/Projected FCF is ranked higher than
82% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. UTHR: 1.10 )
Ranked among companies with meaningful Price/Projected FCF only.
UTHR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 3.8 Max: 232.67
Current: 1.1
0.83
232.67
Price/Median PS Value 0.80
UTHR's Price/Median PS Value is ranked higher than
64% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. UTHR: 0.80 )
Ranked among companies with meaningful Price/Median PS Value only.
UTHR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 1.42 Max: 277.71
Current: 0.8
0.55
277.71
Price/Peter Lynch Fair Value 0.40
UTHR's Price/Peter Lynch Fair Value is ranked higher than
96% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 1.63 vs. UTHR: 0.40 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
UTHR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.21  Med: 1.02 Max: 5.82
Current: 0.4
0.21
5.82
Price/Graham Number 1.26
UTHR's Price/Graham Number is ranked higher than
74% of the 197 Companies
in the Global Biotechnology industry.

( Industry Median: 2.44 vs. UTHR: 1.26 )
Ranked among companies with meaningful Price/Graham Number only.
UTHR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.77  Med: 2.49 Max: 6.18
Current: 1.26
0.77
6.18
Earnings Yield (Greenblatt) (%) 20.20
UTHR's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. UTHR: 20.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
UTHR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 5.9 Max: 40.2
Current: 20.2
0.8
40.2
Forward Rate of Return (Yacktman) (%) 36.75
UTHR's Forward Rate of Return (Yacktman) (%) is ranked higher than
88% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 15.03 vs. UTHR: 36.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
UTHR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.4  Med: 1.2 Max: 56.9
Current: 36.75
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,595
EPS (TTM) $ 14.87
Beta1.38
Short Percentage of Float19.73%
52-Week Range $97.52 - 153.08
Shares Outstanding (Mil)42.42

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,609 1,727 1,576 1,574
EPS ($) 14.01 15.65 15.47 14.60
EPS w/o NRI ($) 14.01 15.65 15.47 14.60
EPS Growth Rate
(3Y to 5Y Estimate)
0.49%
Dividends Per Share ($)
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
Worst Performance YTD: MasterCard, Lazard Aug 03 2016 
5 Mid-Cap Stocks With Low Enterprise Multiples Aug 03 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
United Therapeutics Is a Value Investor's Biotech Dream Apr 28 2016 
Cummins and Deckers are Candidates for a January Bounce Nov 20 2015 
Estimated Revenue Up 5% Stock Screen Nov 18 2015 

More From Other Websites
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
New Strong Buy Stocks for January 5th Jan 05 2017
United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference Jan 05 2017
United Therapeutics' PAH Suite Bodes Well, Competition Rife Dec 29 2016
United Therapeutics: Will RemoSynch Become a Key Growth Driver? Dec 29 2016
United Therapeutics’ Robust Research Pipeline Dec 29 2016
United Therapeutics: Will Orenitram See Strong Patient Demand? Dec 28 2016
United Therapeutics: Why Tyvaso Is Still a Key Growth Driver Dec 28 2016
Why United Therapeutics Expects Strong Revenue Growth Dec 28 2016
Coverage initiated on United Therapeutics by Oppenheimer Dec 15 2016
Are there buying opportunities in health care? Dec 07 2016
Hedge Funds Are Selling Patterson Companies, Inc. (PDCO) Dec 02 2016
Pig organs to save lives by end of decade: United Therape... Dec 01 2016
Hedge Funds Are Buying WellCare Health Plans, Inc. (WCG) Dec 01 2016
United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US :... Nov 09 2016
Palo Alto Investors’s Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and... Nov 08 2016
Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)